OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost bought 200,000 shares of the firm's stock in a transaction dated Thursday, September 15th. The shares were acquired at an average price of $2.06 per share, for a total transaction of $412,000.00. Following the completion of the transaction, the chief executive officer now owns 197,456,694 shares in the company, valued at approximately $406,760,789.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Phillip Md Et Al Frost also recently made the following trade(s):
Get
OPKO Health alerts:
- On Wednesday, August 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.54 per share, for a total transaction of $508,000.00.
- On Friday, August 5th, Phillip Md Et Al Frost bought 350,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.29 per share, for a total transaction of $801,500.00.
- On Tuesday, June 21st, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The stock was purchased at an average price of $2.39 per share, for a total transaction of $478,000.00.
OPKO Health Price Performance
NASDAQ:OPK opened at $2.05 on Friday. The firm has a market cap of $1.58 billion, a PE ratio of -7.07 and a beta of 1.75. OPKO Health, Inc. has a 12 month low of $1.96 and a 12 month high of $5.25. The company has a quick ratio of 1.91, a current ratio of 2.30 and a debt-to-equity ratio of 0.12. The company's 50-day moving average price is $2.42 and its two-hundred day moving average price is $2.81.
OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). OPKO Health had a negative net
margin of 14.18% and a negative return on equity of 7.72%. The firm had revenue of $309.90 million during the quarter, compared to analyst estimates of $326.87 million. During the same quarter last year, the firm earned ($0.03) earnings per share. OPKO Health's quarterly revenue was down 30.0% on a year-over-year basis. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Piper Sandler reduced their price target on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Friday, August 5th.
Hedge Funds Weigh In On OPKO Health
Large investors have recently modified their holdings of the stock. Swiss National Bank lifted its position in shares of OPKO Health by 7.5% during the first quarter. Swiss National Bank now owns 1,047,200 shares of the biotechnology company's stock worth $3,602,000 after purchasing an additional 72,900 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of OPKO Health by 19.2% during the fourth quarter. BNP Paribas Arbitrage SA now owns 165,928 shares of the biotechnology company's stock worth $798,000 after purchasing an additional 26,707 shares in the last quarter. Columbia Asset Management acquired a new position in shares of OPKO Health during the fourth quarter worth approximately $67,000. E Fund Management Co. Ltd. lifted its position in shares of OPKO Health by 190.1% during the first quarter. E Fund Management Co. Ltd. now owns 81,338 shares of the biotechnology company's stock worth $280,000 after purchasing an additional 53,299 shares in the last quarter. Finally, Levin Capital Strategies L.P. acquired a new position in shares of OPKO Health during the first quarter worth approximately $52,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
OPKO Health Company Profile
(Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Featured Stories
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
